The meta-analysis has been an invaluable tool in the evaluation of adjuvant therapy for breast cancer and has supported the use of tamoxifen, anthracyclines, and taxanes via the compilation of results from small trials that individually yielded less than dramatic results. Indeed, recent results of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis demonstrated the enduring benefit in 15-year recurrence-free and overall survival for 5 years of adjuvant tamoxifen for women of any age with earlystage steroid receptor-positive breast cancer (1). It also confirmed an age-related increase in the risks of thromboembolic events and endometrial cancer without an excess in non-breast cancer-related deaths.
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In recent years, the use of tamoxifen in postmenopausal women has been eclipsed by enthusiasm about aromatase inhibitors. Multiple studies have documented a greater reduction in breast cancer recurrence and a seemingly more favorable toxicity profile with aromatase inhibitors compared with tamoxifen, which has led to their widespread use over tamoxifen, despite the fact that an overall survival benefit with this approach has not been observed. These results have led to guidelines by entities such as the American Society of Clinical Oncology (2) and the National Comprehensive Cancer Network (3) stating that aromatase inhibitors should be considered in place of or in sequence with tamoxifen for most postmenopausal women with early-stage hormone receptor-positive breast cancer.
The emergence of data from large trials of adjuvant aromatase inhibitors has enabled several meta-analyses to be performed, one of which is reported by Amir et al. (4) in this issue of the Journal. The authors hypothesized that the relative toxicity of aromatase inhibitors compared with tamoxifen could explain the discordant observation of their improved benefit in disease-free survival without enhanced overall survival benefit. Their meta-analysis was restricted to seven randomized controlled trials that enrolled 30 023 patients and compared 5 years of aromatase inhibitor, 5 years of tamoxifen, or a switch from one to the other as primary endocrine therapy. In addition to conventional breast cancer endpoints, they focused on six prespecified serious adverse events-cardiovascular disease, cerebrovascular disease, bone fracture, thromboembolic events, endometrial carcinoma, and other non-breast cancers. In large part, the analysis confirmed what we already know: Compared with tamoxifen, the use of aromatase inhibitors was associated with a statistically significant increase in bone fractures and decrease in endometrial cancer and thromboembolic events and no difference in the risks of second cancers. What we learned, however, was that there was no difference in the risk of cerebrovascular disease with tamoxifen compared with aromatase inhibitors, and the risk of cardiovascular disease was statistically significantly higher with aromatase inhibitors compared with tamoxifen, although the magnitude of the difference was small-an absolute difference in risk of 0.8% and a number needed to harm of 132. It is notable that use of up-front aromatase inhibitors was also associated with a nonstatistically significantly higher odds of death without breast cancer recurrence compared with the use of tamoxifen alone or switching from tamoxifen to aromatase inhibitors (odds ratio = 1.11, 95% confidence interval = 0.98 to 1.26, P = .09). Of particular interest was the finding that those treated with a switching strategy had a statistically significant reduction in the odds of death without breast cancer recurrence compared with those treated with 5 years of tamoxifen or 5 years of an aromatase inhibitor alone (odds ratio = 0.87, 95% 95% confidence interval = 0.77 to 0.99, P = .03). In absolute terms, the difference is exceedingly small-a 0.2% difference in absolute risk of death without breast cancer recurrence. From these findings, Amir et al. (4) concluded that the switching strategy allows patients to reap the positive benefits of the aromatase inhibitors while limiting potential toxicity.
The analysis by Amir et al. (4) should be considered in the context of another recent meta-analysis from the EBCTCG of breast cancer outcomes in adjuvant trials of aromatase inhibitors vs tamoxifen in postmenopausal women (5) . These two meta-analyses differ in several ways. First, the EBCTCG compared two cohortscohort 1, which received 5 years of tamoxifen vs 5 years of an aromatase inhibitor and cohort 2, which received 5 years of tamoxifen vs the switch from tamoxifen to an aromatase inhibitorwhereas the meta-analysis by Amir et al. (7), whereas the EBCTCG study did not. Ultimately, with 5 years of follow-up, the EBCTCG meta-analysis showed that cohort 1 aromatase inhibitor recipients had a 2.9% absolute decrease in recurrence, a 1.1% decrease in breast cancer mortality, a 0.2% increase in death without recurrence, and a 0.8% decrease in death from any cause, with only the first result achieving statistical significance. At 3 years jnci.oxfordjournals.org JNCI | Editorials 1281 from treatment divergence (5 years after starting hormonal treatment), the cohort 2 switch recipients showed a statistically significant improvement in recurrence (absolute benefit of 3.1%), breast cancer mortality (absolute benefit of 0.7%), and death from any cause (absolute benefit of 1.1%), and a non-statistically significant reduction in death without breast cancer recurrence (absolute benefit of 0.4%) (5).
Of note, neither meta-analysis included extended adjuvant approaches beyond 5 years, and both excluded data from the switching arms of the Breast International Group 01-98 trial (BIG 1-98). The exclusion of such critical data could have altered the results of either meta-analysis, although the BIG 1-98 trial did not show a difference in breast cancer recurrence, breast cancer deaths, or non-breast cancer deaths for letrozole monotherapy, switching from letrozole to tamoxifen, or switching from tamoxifen to letrozole (8) . It could be argued that omitting the switching strategy arms of BIG 1-98 from both meta-analyses and the lack of data from TEAM in the EBCTCG meta-analysis are critical gaps because the most important question in current clinical practice for many is not the comparison of a switching strategy with 5 years of tamoxifen, but rather a comparison of a switching strategy with 5 years of aromatase inhibitor, a question that can only be answered by these trials.
Other studies of aromatase inhibitor use also enhance our understanding of the side effects and efficacy of these agents. For example, the National Cancer Institute of Canada MAP.3 chemoprevention study of exemestane vs placebo showed a reduction in invasive breast cancer and no excess cardiovascular events with median follow-up of 3 years (9), and the National Cancer Institute of Canada MA-27 adjuvant therapy study showed no material differences between two different aromatase inhibitors, letrozole and exemestane, in benefit or toxicity (10) . Finally, compliance is a critical determinant of outcomes for all patients, and several studies have raised concerns about long-term adherence and compliance with both aromatase inhibitors and tamoxifen. Differential compliance could certainly contribute to small differences in outcome, but it was not evaluated in this metaanalysis (11).
What we lack today is a predictive model that integrates cardiovascular and bone risks with the risk of breast cancer recurrence to facilitate a personalized selection of therapy. The BIG 1-98 investigators have taken the first step by deriving a composite risk model that includes estrogen and progesterone receptor expression, Ki-67, HER2 expression, tumor size, and lymph node status to stratify patients into a high-risk group (which benefited more from letrozole monotherapy), an intermediate-risk group (which did equally well with letrozole or switching strategies), and a low-risk group (which benefited from any endocrine approach) (12) . The ability to incorporate cardiovascular and bone health into such a model that is intuitive and easy to useperhaps an enhanced version of the Adjuvant! Online formatwould be of great use to doctors and patients. We hope that, with time, more sophisticated prognostic and predictive testing for breast cancer and non-breast cancer-related endpoints will become the norm.
Finally, the provocative findings from both the Amir et al. (4) and EBCTCG meta-analyses are far from mature given that the length of follow-up of trials of adjuvant aromatase inhibitors is still relatively short. Notably, survival benefits with adjuvant tamoxifen were not truly evident until after 5 years of follow-up. Thus, it is conceivable that a late survival advantage with aromatase inhibitors over tamoxifen may also emerge over time. Moreover, although it appears that the risk of fracture reverts to baseline after cessation of aromatase inhibitors, it is uncertain whether cardiovascular risk will also evolve over time.
It is also important to emphasize that the absolute differences in the endpoints examined-whether toxicity or efficacy-albeit statistically significant, were small. Ongoing uncertainty about the optimal endocrine approach for postmenopausal women with early-stage breast cancer was reflected in the recommendations of the 2011 St Gallen consensus panel, whose members were equally divided about whether all postmenopausal patients should receive an aromatase inhibitor at some point in their treatment or not (13). The panelists felt that certain patients could be treated with tamoxifen alone, whereas others (eg, lymph node-positive patients) would be best served by receiving an up-front aromatase inhibitor. A practical approach while we await further maturation of adjuvant endocrine data would be to choose initial endocrine therapy for the individual patient with careful attention to the risk of breast cancer recurrence, the risk of toxicity, and comorbidities. Ultimately, results of the metaanalysis by Amir et al. (4) as well as those from the EBCTCG meta-analysis suggest that switching strategies are also rational and effective, leading us to conclude that we should not "ditch the switch."
